SciRhom - Targeting autoimmunity at its core

SciRhom, a clinical-stage company, has identified iRhom2 to be a key regulator that imparts substrate specificity to the protease activity of TACE/ADAM17, an enzyme essential to pro-inflammatory signaling and immune/tissue homeostasis. Given this pivotal role played by iRhom2 in simultaneously inhibiting multiple disease-relevant pathways, the company aims to develop first-in-class anti-iRhom2 antibodies and provide a new paradigm for treating I&I diseases .